Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Viktoria Odelga, MD, Jutta Ackermann, Verena Sagaster, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2007) 110 (11): 4845.

https://doi.org/10.1182/blood.V110.11.4845.4845

Published: 2007

Journal Articles

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andreas Chott, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2006) 108 (11): 2753.

https://doi.org/10.1182/blood.V108.11.2753.2753

Published: 2006

Journal Articles

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Johannes Drach, MD, Verena Sagaster, MD, Victoria Odelga, MD, Hannes Kaufmann, MD, Jutta Ackermann, Markus Galhuber, Niklas Zojer, MD, Elisabeth Küenburg, MD, Christoph Zielinski, MD, Rotraud Wieser, MD, Heinz Ludwig, MD

Blood (2006) 108 (11): 3398.

https://doi.org/10.1182/blood.V108.11.3398.3398

Published: 2006

Journal Articles

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Johannes Drach, MD, Sonja Seidl, MD, Oskar Pichelmayer, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2005) 106 (11): 4799.

https://doi.org/10.1182/blood.V106.11.4799.4799

Published: 2005

Journal Articles

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

Johannes Drach, MD, E. Kuenburg, MD, Verena Sagaster, MD, Niklas Zojer, MD, Hannes Kaufmann, MD, Jutta Ackermann, Heinz Ludwig, MD

Blood (2005) 106 (11): 509.

https://doi.org/10.1182/blood.V106.11.509.509

Published: 2005

Journal Articles

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Johannes Drach, MD, Jutta Ackermann, Catrin Baldia, MD, Hannes Kaufmann, MD, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Sonja Seidl, MD, Verena Sagaster, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ulrich Jaeger, MD, Christoph Zielinski, MD

Blood (2004) 104 (11): 4873.

https://doi.org/10.1182/blood.V104.11.4873.4873

Published: 2004

Journal Articles

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Hannes Kaufmann, MD, Catrin Baldia, MD, Jutta Ackermann, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Ulrich Jaeger, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ingrid Simonitsch-Klupp, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2004) 104 (11): 3459.

https://doi.org/10.1182/blood.V104.11.3459.3459

Published: 2004

Journal Articles

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Hannes Kaufmann, Markus Raderer, Stefan Wöhrer, Andreas Püspök, Alexander Bankier, Christoph Zielinski, Andreas Chott, Johannes Drach

Blood (2004) 104 (8): 2269–2271.

https://doi.org/10.1182/blood-2004-03-1091

Published: 2004

Journal Articles

Thromboembolic events during treatment with thalidomide

Eleonora Urbauer, Hannes Kaufmann, Thomas Nösslinger, Markus Raderer, Johannes Drach

Blood (2002) 99 (11): 4247–4248.

https://doi.org/10.1182/blood-2001-12-0245

Published: 2002

Journal Articles

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Niklas Zojer, Robert Königsberg, Jutta Ackermann, Elke Fritz, Susanne Dallinger, Elisabeth Krömer, Hannes Kaufmann, Lucia Riedl, Heinz Gisslinger, Susanne Schreiber, Renate Heinz, Heinz Ludwig, Heinz Huber, Johannes Drach

Blood (2000) 95 (6): 1925–1930.

https://doi.org/10.1182/blood.V95.6.1925

Published: 2000

NARROW

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Thromboembolic events during treatment with thalidomide

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only